Granlibakken Tahoe Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2004



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Protein Kinases and Cancer: The Promise of Molecular-Based Therapies (C3)


Organizer(s) Judith S. Sebolt-Leopold and Charles L. Sawyers
February 24—29, 2004
Granlibakken Tahoe • Tahoe City, California USA
Abstract Deadline: Oct 23, 2003
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Dec 23, 2003

Sponsored by Amgen Inc.

Summary of Meeting:
Upon completion of this conference, participants should be able to: - Discuss progress made in the cancer research community showing that kinases are druggable targets. - Recognize key signal transduction pathways amenable to pharmacological intervention by kinase inhibitors. - Discuss the critical importance of translational assays in driving clinical trial design of kinase-targeted therapies. - Discuss the application of technologies, encompassing proteomics, genomics, and structural biology, for facilitating novel drug discovery. - Discuss the challenges facing oncologists in deciphering the complexities of individual tumor signaling. - Integrate multidisciplinary leaders involved in basic research, pharmaceutical discovery, and clinical oncology in order to provide all with a better understanding of the numerous steps involved in going from bench to bedside. - Develop new collaborations among the scientists in attendance as well as new insights leading to novel and effective interventions.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


TUESDAY, FEBRUARY 24

15:00—19:00
Registration

Pre-Function
19:15—19:30
Orientation

Mountain/Lake Rooms
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake Rooms
Robert E. Wittes, Memorial Sloan-Kettering Cancer Center, USA
A Clinical Perspective on the Future of Kinase-Targeted Therapies


WEDNESDAY, FEBRUARY 25

07:00—08:00
Breakfast

Granhall
08:00—11:15
Therapies Targeting Growth Factor Receptors: The ErbB Family and Associated Signaling
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake Rooms
* Carlos L. Arteaga, Vanderbilt University School of Medicine, USA
Predictors of Response and Resistance to Erbb Tyrosine Kinase Inhibitors

Lewis A. Chodosh, University of Pennsylvania School of Medicine, USA
Inducible Transgenic Models for Breast Cancer Progression and Target Validation

Mark X. Sliwkowski, Genentech, Inc., USA
Targeting Ligand Activated ErbB2/HER2 in Solid Tumors

Tomi K. Sawyer, CMD BIoscience, USA
Novel Dual Src/Abl Kinase Inhibitors for Cancer Therapy

Geoffrey W. Krystal, Virginia Commonwealth University, USA
Short Talk: The Combination of STI571 and a Novel IGF-1R Kinase Inhibitor Efficiently Blocks PI3K-Akt Activity, Inhibits Growth and Promotes Apoptosis in SCLC

Sang Hoon Lee, ABL Bio, South Korea
Short Talk: In vivo Anti-Angiogenic and Anti-Tumor Activity is Associated with Target Modulation by CHIR258, a Small Molecule Inhibitor of Receptor Tyrosine Kinases

09:20—09:40
Coffee Break

Pre-Function
11:15—13:00
Poster Setup

Bay Room
13:00—22:00
Poster Viewing

Bay Room
16:30—17:00
Coffee & Snacks Available

Pre-Function
17:00—19:15
Additional Kinase Approaches with Therapeutic Promise
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake Rooms
* Douglas Hanahan, ISREC, Switzerland
An Overview of Angiogenic-Directed Approaches

George F. Vande Woude, Van Andel Research Institute, USA
Met-HGF/SF in Human Malignancy

Anita B. Roberts, National Institutes of Health, USA
TGF-beta/Smad Signaling: Dual Tumor Suppressor and Pro-Metastatic Activities

Jonathan M. Yingling, Idera Pharmaceuticals, Inc., USA
TGF-beta Receptor Kinase Inhibitors: A Novel Cancer Therapy

19:15—20:15
Dinner

Granhall
20:00—22:30
Poster Session 1

Bay Room
20:00—21:00
Social Hour

Bay Room

THURSDAY, FEBRUARY 26

07:00—08:00
Breakfast

Granhall
08:00—11:00
The MAP Kinase Pathway: Multiple Targets for Pharmacological Intervention
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake Rooms
Daniel G. Gioeli, University of Virginia, USA
Signal Transduction in Prostate Cancer Progression

* Judith Sebolt-Leopold, , USA
Attractiveness of Targeting MEK for Anticancer Drug Development

Richard M. Marais, Cancer Research UK Manchester Institute, UK
B-Raf Mutations in Human Cancer: Implications for Development of Improved Therapies

Michelle Renee Ward, Chiron Corporation, USA
Short Talk: Amplification of B-raf in Melanoma Cell Lines Identified Using Array Comparative Genomic Hybridization (aCGH)

Rosalie C. Sears, Oregon Health & Science University, USA
Short Talk: c-Myc Protein Degradation is Regulated by Ras Signaling Pathways, the PP2A Phosphatase and the Pin1 Prolyl Isomerase

09:20—09:40
Coffee Break

Pre-Function
11:00—13:00
Poster Setup

Bay Room
13:00—22:00
Poster Viewing

Bay Room
16:30—17:00
Coffee & Snacks Available

Pre-Function
17:00—19:00
Cell Cycle Targets
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake Rooms
* Edward Harlow, Constellation Pharmaceuticals, USA
Synergy between Signaling Pathways

Peter L. Toogood, Lycera Corporation, USA
Discovery of A Selective CDK4 Inhibitor

Nicholas J. Keen, Novartis Institutes for BioMedical Research, USA
Targeting Cytokinesis and the Cell Cycle: Aurora B and CDK1/2 as Unique Targets in Cancer

Martin J.I. Andrews, Cyclacel, Ltd., UK
Short Talk: Inhibition of CDK2- Cyclin A Activity by Blocking Substrate Recruitment

19:00—20:00
Dinner

Bay Room
20:00—22:30
Poster Session 2

Bay Room
20:00—21:00
Social Hour

Bay Room

FRIDAY, FEBRUARY 27

07:00—08:00
Breakfast

Granhall
08:00—11:15
Survival Signaling: The AKT/PI 3-Kinase Pathway
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake Rooms
Gordon B. Mills, University of Texas MD Anderson Cancer Center, USA
Targeting the PI3K Pathway in Cancer

Philip N. Tsichlis, Tufts-New England Medical Center, USA
TPL-2 on a Cancer Target

* Neal Rosen, Memorial Sloan-Kettering Cancer Center, USA
Inhibition of AKT Activation with Ansamycins

Paul Workman, Institute of Cancer Research, UK
Drugging the Cancer Chaperone: Laboratory and Clinical Advances in Targeting Heat Shock Protein 90 (Hsp90)

Jeremy R. Graff, Eli Lilly and Company, USA
Short Talk: Anti-Tumor Activity of the PKCbeta Selective Inhibitor, LY317615: Inhibition of the PI3 Kinase/ AKT Pathway by the Primary Metabolite, LY326020

09:20—09:40
Coffee Break

Pre-Function
11:15—13:00
Poster Setup

Bay Room
13:00—22:00
Poster Viewing

Bay Room
16:30—17:00
Coffee & Snacks Available

Pre-Function
17:00—19:00
Survival Signaling: Inhibition of mTOR(FRAP)
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake Rooms
* Manuel Hidalgo, Johns Hopkins School of Medicine, USA
Overview of mTOR Biology and Therapeutic Approaches

Pamela S. Cohen, Amo Therapeutics, USA
The Clinical Promise of mTOR Targeted Therapy

James J. Gibbons Jr., Wyeth Pharmaceuticals, USA
Enhanced Sensitivity of PTEN-Deficient Tumors to mTOR Inhibition

Amy M. Mingo-Sion, University of Colorado Health Sciences Center, USA
Short Talk: Mammalian Target of Rapamycin Predominantly Regulates Insulin Receptor Substrate-1 Ser312 Phosphorylation in Breast Cancer Cells

19:00—20:00
Dinner

Granhall
20:00—22:30
Poster Session 3

Bay Room
20:00—21:00
Social Hour

Bay Room

SATURDAY, FEBRUARY 28

07:00—08:00
Breakfast

Granhall
08:00—11:15
Impact of Technologies on Future Target Identification
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake Rooms
John Kuriyan, University of California, Berkeley, USA
Auto-Regulation Mechanisms in c-Abl Tyrosine Kinase

Keith P. Wilson, Takeda California, USA
Structures of Active Autoinhibited and Gleeve-Bond C-KIT

Natalie G. Ahn, University of Colorado, USA
A Functional Proteomics Approach to Target Identification

* William R. Sellers, Broad Institute of MIT and Harvard, USA
Phenotypic Screening of Small Molecule Libraries

X. Helen Hua, Enfunding Solution Inc, USA
Short Talk: Enhancing Discovery of Selective Small Molecule Akt Inhibitors Using Biomarkers

J. Guillermo Paez, Dana Farber Cancer Institute, USA
Short Talk: Kinome Re-Sequencing in Human Cancer

09:20—09:40
Coffee Break

Pre-Function
16:30—17:00
Coffee & Snacks Available

Pre-Function
17:00—19:00
Looking Forward: The Impact of Kinase-Targeted Therapies on Patient Survival
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake Rooms
Roger G. Ulrich, RUC Pharmaceutical Development Specialists, USA
Molecular Profiling of Adverse Drug Effects

Christopher E. Sims, University of California, Irvine, USA
Short Talk: Advancing the Field of Signal Transduction One Cell at a Time: Analysis of Single Tumor Cells Using the Laser Micropipet System

* Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, USA
Clinical Reality: How do Oncologists Screen for Signaling Abnormalities?

19:00—20:00
Social Hour

Granhall
20:00—21:00
Dinner

Mountain/Lake Rooms
21:00—00:00
Entertainment

Mountain/Lake Rooms

SUNDAY, FEBRUARY 29

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13CA105863-01




We gratefully acknowledge additional support for this conference from:


Cell Signaling Technology, Inc.
Educational donation provided by Amgen
Pfizer Inc. Wyeth Research Labs

Cell Signaling Technology, Inc.
 

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676